Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Navigating the future of cell therapies with bit.bio exec Kathryn Corzo

By Brian Buntz | August 28, 2023

Kathryn Corzo

Kathryn Corzo is currently the president and chief operating officer of bit.bio. The Cambridge, UK–based synthetic biology company specializes in providing human cells for research, drug discovery and cell therapy.

Her previous roles include a stint as the head of development for oncology cell therapies at Takeda. She also led the North American Innovation Center and R&D Digital Accelerator at Sanofi and held a leadership role in Lilly’s oncology business unit.

Bit.bio’s differentiated approach

Corzo’s decision to join bit.bio was rooted in the company’s pioneering approach to cell therapy. “Joining bit.bio became a clear choice,” she recalls. “The platform technology at bit.bio offers a solution to some of the significant challenges in the cell therapy field, mainly by manufacturing consistent cells at scale, speed and reduced costs thus democratizing access to human cells.”

The company’s precision cell-programming technology, opti-ox, uses genomic safe harbor sites to accurately execute genetic code in mammalian cells. opti-ox enables the precise, efficient and scalable reprogramming of stem cells into any desired mature cell type. “We aspire for our cells to become the benchmark for disease models,” Corzo said.

Bit.bio employs a screening method to identify specific transcription factor combinations, then uses its opti-ox technology to precisely, consistently and efficiently produce human cell types with a desired maturity and function.

Strengthening opti-ox’s potential with strategic alliances

To expand the reach of opti-ox, bit.bio is forging strategic partnerships. “A recent example is our collaboration with BlueRock Therapeutics to work on T regs, a promising cell type for immunological applications,” Corzo said. In the alliance with BlueRock, bit.bio will use its machine learning-powered discovery platform to pinpoint transcription factor combinations for reprogramming induced pluripotent stem cells (iPSCs) into Tregs. Under the terms of the deal, BlueRock has an option to license the opti-ox precision cell programming technology to control the expression of transcription factor combinations within Treg cell therapies.

The alliance with BlueRock represents a true partnership, Corzo said, which “capitalizes on the unique skills of both parties.” “Collaborations and partnerships are about leveraging strengths and innovation across new technologies and platforms to speed development of new therapies,” she continued. “What makes the biotech and drug development world so vibrant is its collaborative spirit.”

Genome engineering meets opti-ox: The Synthego collaboration

In addition, bit.bio has recently expanded a strategic alliance with genome engineering company Synthego. The collaboration unites Synthego’s background in genome editing with opti-ox technology to develop novel cell therapies. The aim is to use the multiplexed opti-ox engineering approach to optimize the number of engineering steps. The technique could potentially shorten clinical cell engineering and development timelines by up to 10 months.

Bit.bio’s international collaboration partners include Charles River Laboratories. It also has distribution partnerships with U.K.-based antibody specialist Abcam, Tokyo’s biotech hub Cosmo Bio and Brazil’s innovative biotech firm, Pensa Bio.

A culture of diversity

Within the walls of bit.bio, the culture is no less diverse. “When you visit bit.bio, you’ll notice the diversity immediately. I believe that diversity drives innovation,” Corzo said. Not just limited to ethnic or gender diversity, bit.bio places a strong emphasis on intellectual variety, she added. “We also embrace diversity of thought and expertise by bringing in perspective from experts in diverse fields such as engineers, gene editors, biologists and bioinformatic specialists.”

Corzo is determined to democratize access to human cells, stating, “I envision a future where our therapies reach millions, not just a few thousands.”


Filed Under: Cell & gene therapy, Oncology, Women in Pharma and Biotech
Tagged With: Bit Bio, BlueRock Therapeutics, cell programming, Kathryn Corzo, Opti-Ox technology, strategic partnerships, Synthego
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

The AI Meets Life Sci podcast with Kayleen Brown and Brian Buntz explores AI's role in healthcare, pharmaceuticals, biotech, medtech and more.
When will drug development have its ChatGPT moment? Inside ambitious AI initiatives at Sanofi and Medable
squirrel in the grass
Fauna Bio CEO on tapping extreme mammals for human disease breakthroughs
ATOMIC
Inside Amgen’s ATOMIC strategy to use ML to accelerate clinical trials
Caribou Biosciences
Caribou Biosciences’ CEO discusses CRISPR progress, future goals, and gender equality in biotech
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE